Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL4705734 | 0.95 | LMNA (0.44) | LMNACES2ESR2TRPA1 | |
| SCHEMBL41691 | 0.79 | ALDH1A1 (0.40) | LMNAESR2TRIM24TRIM33 | |
| SCHEMBL2709914 | 0.79 | TRIM24 (0.33) | LMNACES2ESR2TRIM24TRIM33 | |
| SCHEMBL8483543 | 0.78 | CES2 (0.33) | LMNACES2ESR2 | |
| SCHEMBL11203735 | 0.77 | LMNA (0.54) | LMNACES2TRPA1 | |
| SCHEMBL12326589 | 0.75 | CA1 (0.31) | ESR2TRIM24TRIM33 | |
| SCHEMBL3597999 | 0.75 | ALDH1A1 (0.43) | LMNAESR2TRIM24TRIM33 | |
| SCHEMBL10779826 | 0.75 | LMNA (0.47) | LMNACES2ESR2TRPA1 | |
| SCHEMBL12326782 | 0.75 | TRIM24 (0.30) | ESR2TRIM24TRIM33 | |
| SCHEMBL15106032 | 0.75 | CES2 (0.38) | LMNACES2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112430632-B | Preparation method of 2- ((trans) -4-aminocyclohexyl) isopropanol | 上海合全药物研发有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-112430632-A | Preparation method of 2- ((trans) -4-aminocyclohexyl) isopropanol | 上海合全药物研发有限公司 | 2021-03-02 | — | — | CN | claimed |
| CN-112430632-B | Preparation method of 2- ((trans) -4-aminocyclohexyl) isopropanol | 上海合全药物研发有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-112430632-B | Preparation method of 2- ((trans) -4-aminocyclohexyl) isopropanol | 上海合全药物研发有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-112430632-A | Preparation method of 2- ((trans) -4-aminocyclohexyl) isopropanol | 上海合全药物研发有限公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-112430632-A | Preparation method of 2- ((trans) -4-aminocyclohexyl) isopropanol | 上海合全药物研发有限公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| EP-2582692-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011159854-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159854-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | LMNA 4185/4885CES2 809/4885ESR2 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.